Thomas James Doyle is VP at Kura Oncology, Inc. (KURA). They have made 7 open-market trades across 1 company since 2023, most recently 2026-09-28.
CIK 0001910331
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KURA | 142,428 | $1.4M |
Shares reported on the most recent Form 4, priced at the 2026-09-29 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KURA | SELL | 2026-09-28 | 2026-09-29 | $10.50 | $48K | -2.4% | — | — |
| KURA | SELL | 2026-01-27 | 2026-01-27 | $8.46 | $42K | -7.2% | +2.5% | +7.6% |
| KURA | SELL | 2025-11-14 | 2025-11-14 | $11.18 | $101K | +7.4% | -5.4% | -28.1% |
| KURA | SELL | 2025-09-29 | 2025-09-29 | $8.94 | $41K | +15.3% | +15.4% | +17.5% |
| KURA | SELL | 2025-01-28 | 2025-01-28 | $7.87 | $39K | +12.3% | -0.6% | -15.5% |
| KURA | SELL | 2024-01-29 | 2024-01-31 | $17.80 | $41K | +0.2% | +6.0% | -3.6% |
| KURA | SELL | 2023-01-27 | 2023-01-31 | $13.89 | $22K | -10.9% | -18.5% | -25.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.